TaiGen Biotech Eyes Pneumonia Antibiotic On China's Market By Year End
This article was originally published in PharmAsia News
Executive Summary
TaiGen Biotechnology said China trials of its Taigexyn (nemonoxacin) pneumonia antibiotic are running smoothly and it estimates a $1.6 million market value in China by the end of the year.